The National Cancer Institute (NCI) awarded a $415,259 Project Grant (CFDA 93.396 - Cancer Biology Research) to the Rector & Visitors of the University of Virginia (UVA) to conduct research on the role of long non-coding RNAs in acute myeloid leukemia (AML). The project aims to 1) determine the role of a specific regulatory RNA in primary and relapsed AML, and 2) define the mechanism underlying its deregulation in AML. UVA will leverage transcriptomic and genomic data from AML patients, drug-resistant cell lines, and mouse models to advance the understanding of how enhancer RNAs modulate the RUNX1-ETO/PU.1 axis, a key oncogenic pathway in AML. Completion of this 2-year project could provide insights into regulatory RNA functions in AML and support the development of novel RNA-based therapeutic approaches to target transcription factors and their oncogenic derivatives.
Generated 3/4/25, 7:02 AM